Updates in the Diagnosis and Treatment of Castleman Disease: Expert Perspectives

Released On
December 22, 2020

Expires On
December 22, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology-Oncology, Primary Care

Topic(s)
Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Paradigm Medical Communications, LLC. In collaboration with the Castleman Disease Collaborative Network.

This activity is supported by an educational grant from EUSA Pharma.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to address the educational needs of community and academic physicians specializing in hematology and hematology/oncology. It will also benefit other clinicians who manage patients with Castleman disease (CD).

Program Overview

This activity will cover the latest updates in diagnosing and treating Castleman disease.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with CD
  • Determine evidence-based treatment for CD in alignment with current guidelines

Faculty

David C. Fajgenbaum, MD, MBA, MSc

Assistant Professor of Medicine
Division of Translational Medicine and Human Genetics
University of Pennsylvania
Associate Director, Patient Impact
Penn Orphan Disease Center
Founding Director
Center for Cytokine Storm Treatment & Laboratory
Co-Founder and Executive Director
Castleman Disease Collaborative Network
Philadelphia, PA

Sudipto Mukherjee, MD, PhD, MPH

Assistant Professor of Medicine
Lerner College of Medicine at CWRU
Director of Rare Cancers and Blood Diseases Program
Department of Hematology and Medical Oncology
Leukemia Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education

PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosures

In accordance with ACCME requirements on disclosure, faculty members and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been resolved.

David C. Fajgenbaum, MD, MBA, MSc

  • Grant/Research Support: EUSA Pharma; Janssen Pharmaceuticals, Inc.

Sudipto Mukherjee, MD, PhD, MPH

  • Consulting Fees: Bristol-Myers Squibb Company; Novartis
  • Speakers Bureau: EUSA Pharma
  • Grant/Research Support: Celgene Corporation

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Independent peer and patient reviewers have no financial relationships to disclose.

Resolution of Conflict of Interest

Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Instructions for Participation

To receive a CME certificate of participation, you should:

  • Follow instructions to register or log in with your professional information and complete the pre-activity assessment.
  • View the online activity in its entirety.
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest.
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or cme@paradigmmc.com

There is no fee required for participation in this activity

Hardware/Software Requirements

This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)

Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF Documents

This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support

If you have any technical problems or playback issues email us at contactus@paradigmmc.com.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer

This CME activity represents the views and opinions of the individual faculty members, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Contact Information

For CME questions please contact: contactus@paradigmmc.com.